Tyra Biosciences, Inc. (NASDAQ:TYRA) Director Sells $126,719.91 in Stock

Tyra Biosciences, Inc. (NASDAQ:TYRA) Director Nina S. Kjellson sold 7,779 shares of Tyra Biosciences stock in a transaction on Thursday, January 16th. The shares were sold at an average price of $16.29, for a total value of $126,719.91. Following the completion of the transaction, the director now owns 447,857 shares of the company’s stock, valued at approximately $7,295,590.53. This trade represents a 1.71 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Tyra Biosciences Stock Down 1.7 %

NASDAQ TYRA opened at $15.91 on Wednesday. The firm has a market cap of $805.05 million, a price-to-earnings ratio of -9.88 and a beta of 1.04. The company has a 50-day simple moving average of $15.38 and a two-hundred day simple moving average of $19.20. Tyra Biosciences, Inc. has a 12-month low of $12.34 and a 12-month high of $29.60.

Tyra Biosciences (NASDAQ:TYRA) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by ($0.01). Equities analysts expect that Tyra Biosciences, Inc. will post -1.57 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on TYRA shares. Wedbush reaffirmed an “outperform” rating and set a $28.00 target price on shares of Tyra Biosciences in a report on Friday, October 25th. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price objective on shares of Tyra Biosciences in a research note on Monday, January 13th. Bank of America upgraded shares of Tyra Biosciences from a “neutral” rating to a “buy” rating and increased their target price for the stock from $22.00 to $31.00 in a research note on Friday, October 18th. Finally, UBS Group initiated coverage on shares of Tyra Biosciences in a research report on Tuesday, January 7th. They set a “buy” rating and a $28.00 price target for the company. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Tyra Biosciences currently has a consensus rating of “Buy” and an average price target of $30.50.

Institutional Investors Weigh In On Tyra Biosciences

Several institutional investors have recently added to or reduced their stakes in the company. HighVista Strategies LLC purchased a new stake in shares of Tyra Biosciences during the second quarter worth about $257,000. Franklin Resources Inc. bought a new position in Tyra Biosciences during the 3rd quarter valued at approximately $278,000. Valence8 US LP purchased a new stake in Tyra Biosciences in the 3rd quarter worth approximately $310,000. SG Americas Securities LLC bought a new stake in shares of Tyra Biosciences in the 3rd quarter worth approximately $311,000. Finally, The Manufacturers Life Insurance Company purchased a new position in shares of Tyra Biosciences during the third quarter valued at approximately $333,000. Hedge funds and other institutional investors own 84.14% of the company’s stock.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.